Search

Your search keyword '"Markevärn, Berit"' showing total 65 results
Start Over Author "Markevärn, Berit"
65 results on '"Markevärn, Berit"'

51. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Author

Höglund, Martin, primary, Sandin, Fredrik, additional, Hellström, Karin, additional, Björeman, Mats, additional, Björkholm, Magnus, additional, Brune, Mats, additional, Dreimane, Arta, additional, Ekblom, Marja, additional, Lehmann, Sören, additional, Ljungman, Per, additional, Malm, Claes, additional, Markevärn, Berit, additional, Myhr-Eriksson, Kristina, additional, Ohm, Lotta, additional, Olsson-Strömberg, Ulla, additional, Själander, Anders, additional, Wadenvik, Hans, additional, Simonsson, Bengt, additional, Stenke, Leif, additional, and Richter, Johan, additional

Published
2013
Full Text
View/download PDF

52. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Author

Ejerblad, Elisabeth, primary, Kvasnicka, Hans M., additional, Thiele, Jürgen, additional, Andreasson, Björn, additional, Björkholm, Magnus, additional, Löfvenberg, Eva, additional, Markevärn, Berit, additional, Merup, Mats, additional, Nilssson, Lars, additional, Palmblad, Jan, additional, Samuelsson, Jan, additional, and Birgegård, Gunnar, additional

Published
2013
Full Text
View/download PDF

53. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders

Author

Birgegård, Gunnar, Björkholm, Magnus, Kutti, Jack, Lärfars, Gerd, Löfvenberg, Eva, Markevärn, Berit, Merup, Mats, Palmblad, Jan, Mauritzson, Nils, Westin, Jan, Samuelsson, Jan, Birgegård, Gunnar, Björkholm, Magnus, Kutti, Jack, Lärfars, Gerd, Löfvenberg, Eva, Markevärn, Berit, Merup, Mats, Palmblad, Jan, Mauritzson, Nils, Westin, Jan, and Samuelsson, Jan

Abstract

BACKGROUND AND OBJECTIVES: Although anagrelide is widely used in the treatment of thrombocythemia in myeloproliferative diseases, there is currently limited information on the efficacy and toxicity of its long-term use. This prospective study investigated clinical toxicity and efficacy of anagrelide during two years of treatment. DESIGN AND METHODS: A multicenter, open, phase II study of anagrelide treatment was performed by the Swedish Myeloproliferative Disorder Study Group. The study included 60 patients with thrombocythemia due to myeloproliferative disease, 42 with essential thrombocythemia (ET), 17 with polycythemia vera (PV) and one with myelofibrosis (MF). RESULTS: Complete response (CR), defined as a platelet count <400x10(9)/L in symptomatic patients and < 600x10(9)/L in asymptomatic patients was achieved in 67% of the patients and partial response (PR) in 6%. The response rate was higher in patients with ET than in those with PV (p = 0.05). Primary treatment failure occurred in 27% due to lack of efficacy at a tolerable dose (n=13) or insufficient platelet response without side effects (n=3). In addition, another 14 patients withdrew from treatment before the end of the two-year period due to side effects. Side effects included palpitations (70%), headache (52%), nausea (35%), diarrhea or flatulence (33%), edema (22%) and fatigue (23%). Patients and doctors rated their satisfaction with the anagrelide treatment on a 10-grade scale from 7.6 at 3 months to >9 at 24 months. After two years, 50% (n=30) of the patients continued anagrelide treatment. INTERPRETATION AND CONCLUSIONS: Side effects and toxic discontinuation rates were higher than in previous studies, probably because this is the first long-term prospective study of the feasibility and toxicity of anagrelide treatment. Nevertheless, anagrelide is a valuable alternative for treatment of thrombocythemia in myeloproliferative disorders for patients who tolerate the drug well.

Published
2004

54. Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

Author

Mustjoki, Satu, primary, Richter, Johan, additional, Barbany, Gisela, additional, Ehrencrona, Hans, additional, Dybedal, Ingunn, additional, Fioretos, Thoas, additional, Gedde-Dahl, Tobias, additional, Gjertsen, Bjorn, additional, Hovland, Randi, additional, Jalkanen, Sari E, additional, Josefsen, Dag, additional, Koskenvesa, Perttu, additional, Lassen, Carin, additional, Latvala, Kirsi, additional, Majeed, Waleed, additional, Malm, Claes, additional, Markevärn, Berit, additional, Mosfegh, Ali, additional, Ohm, Lotta, additional, Olofsson, Tor, additional, Olsson-Strömberg, Ulla, additional, Rapakko, Katrin, additional, Remes, Kari, additional, Stentoft, Jesper, additional, Stenke, Leif, additional, Suominen, Merja, additional, Thunberg, Sara, additional, Bjerrum, Ole Weiss, additional, Simonsson, Bengt, additional, Porkka, Kimmo, additional, and Hjorth-Hansen, Henrik, additional

Published
2011
Full Text
View/download PDF

55. Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

Author

Björkholm, Magnus, primary, Derolf, Åsa R., additional, Hultcrantz, Malin, additional, Kristinsson, Sigurdur Y., additional, Ekstrand, Charlotta, additional, Goldin, Lynn R., additional, Andreasson, Björn, additional, Birgegård, Gunnar, additional, Linder, Olle, additional, Malm, Claes, additional, Markevärn, Berit, additional, Nilsson, Lars, additional, Samuelsson, Jan, additional, Granath, Fredrik, additional, and Landgren, Ola, additional

Published
2011
Full Text
View/download PDF

56. The Proportion of Ph+ CD34+CD38neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study

Author

Mustjoki, Satu, primary, Richter, Johan, additional, Barbany, Gisela, additional, Dybedal, Ingunn, additional, Fioretos, Thoas, additional, Gedde-Dahl, Tobias, additional, Gjertsen, Bjorn T., additional, Hovland, Randi, additional, Jalkanen, Sari, additional, Josefsen, Dag, additional, Koskenvesa, Perttu, additional, Lassen, Carin, additional, Latvala, Kirsi, additional, Majeed, Waleed, additional, Malm, Claes, additional, Markevärn, Berit, additional, Moshfegh, Ali, additional, Ohm, Lotta, additional, Olofsson, Tor, additional, Olsson-Strömberg, Ulla, additional, Rapakko, Katrin, additional, Remes, Kari, additional, Stentoft, Jesper, additional, Stenke, Leif, additional, Suominen, Merja, additional, Thunberg, Sara, additional, Bjerrum, Ole Weiss, additional, Simonsson, Bengt, additional, Porkka, Kimmo, additional, and Hjorth-Hansen, Henrik, additional

Published
2010
Full Text
View/download PDF

58. TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

Author

Palmblad, Jan, primary, Björkholm, Magnus, additional, Kutti, Jack, additional, Lärfars, Gerd, additional, Löfvenberg, Eva, additional, Markevärn, Berit, additional, Merup, Mats, additional, Mauritzson, Nils, additional, Westin, Jan, additional, Samuelsson, Jan, additional, and Birgegård, Gunnar, additional

Published
2008
Full Text
View/download PDF

60. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Author

Kreutzman, Anna, Yadav, Bhagwan, Brümmendorf, Tim Henrik, Gjertsen, Bjorn Tore, Hee Lee, Moon, Janssen, Jeroen, Kasanen, Tiina, Koskenvesa, Perttu, Lotfi, Kourosh, Markevärn, Berit, Olsson-Strömberg, Ulla, Stentoft, Jesper, Stenke, Leif, Söderlund, Stina, Udby, Lene, Richter, Johan, Hjorth-Hansen, Henrik, and Mustjoki, Satu

Subjects
3. Good health
Abstract

OncoImmunology 8(9), e1638210 (2019). doi:10.1080/2162402X.2019.1638210, Published by Taylor & Franics, Abingdon

61. Imatinib or dasatinib treatment of chronic myeloid leukemia reduces circulating myeloid-derived suppressor cells but increases their CD40 expression

Author

Christiansson, Lisa, Söderlund, Stina, Hjorth-Hansen, Henrik, Höglund, Martin, Markevärn, Berit, Richter, Johan, Stenke, Leif, Simonsson, Bengt, Mustjoki, Satu, Loskog, Angelica S I, Olsson-Strömberg, Ulla, Christiansson, Lisa, Söderlund, Stina, Hjorth-Hansen, Henrik, Höglund, Martin, Markevärn, Berit, Richter, Johan, Stenke, Leif, Simonsson, Bengt, Mustjoki, Satu, Loskog, Angelica S I, and Olsson-Strömberg, Ulla

62. Mature, Adaptive-like CD56DIMNK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Author

Ilander, Mette, Schlums, Heinrich, Olsson-Strömberg, Ulla, Lähteenmäki, Hanna, Kasanen, Tiina, Koskenvesa, Perttu, Söderlund, Stina, Höglund, Martin, Markevärn, Berit, Själander, Anders, Lotfi, Kourosh, Malm, Claes, Lubking, Anna, Ekblom, Marja, Holm, Elena, Björeman, Mats, Lehmann, Sören, Stenke, Leif, Ohm, Lotta, Majeed, Waleed, Muller, Martin C., Ehrencrona, Hans, Hjorth-Hansen, Henrik, Saussele, Susanne, Mahon, Francois-Xavier, Porkka, Kimmo, Guilhot, Joelle, Bryceson, Yenan, Richter, Johan, and Mustjoki, Satu

Published
2015
Full Text
View/download PDF

63. The Proportion of Ph+ CD34+CD38negLeukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study

Author

Mustjoki, Satu, Richter, Johan, Barbany, Gisela, Dybedal, Ingunn, Fioretos, Thoas, Gedde-Dahl, Tobias, Gjertsen, Bjorn T., Hovland, Randi, Jalkanen, Sari, Josefsen, Dag, Koskenvesa, Perttu, Lassen, Carin, Latvala, Kirsi, Majeed, Waleed, Malm, Claes, Markevärn, Berit, Moshfegh, Ali, Ohm, Lotta, Olofsson, Tor, Olsson-Strömberg, Ulla, Rapakko, Katrin, Remes, Kari, Stentoft, Jesper, Stenke, Leif, Suominen, Merja, Thunberg, Sara, Bjerrum, Ole Weiss, Simonsson, Bengt, Porkka, Kimmo, and Hjorth-Hansen, Henrik

Abstract

Abstract 667

Published
2010
Full Text
View/download PDF

64. A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Author

Simonsson, Bengt, Gedde-Dahl, Tobias, Markevärn, Berit, Remes, Kari, Stentoft, Jesper, Almqvist, Anders, Björeman, Mats, Flogegård, Max, Hallman, Heikki, Koskenvesa, Perttu, Lindblom, Anders, Malm, Claes, Mustjoki, Satu, Myhr-Eriksson, Kristina, Räsänen, Anu, Sinisalo, Marjatta, Sippola, Risto, Själander, Anders, Strömberg, Ulla, Bjerrum, Ole Weiss, Ehrencrona, Hans, Gruber, Franz, Kairisto, Veli, Olsson, Karin RN, Nagler, Arnon, Nielsen, Johan Lanng, Hjorth-Hansen, Henrik, and Porkka, Kimmo

Abstract

Imatinib mesylate (IM) 400 mg once daily (OD) is the current standard first-line therapy for CML. Several biological and clinical observations suggest that combining IM with interferon alpha (IFNa) may improve the outcome of treatment.To compare the effects of standard-dose IM to combination of IM and IFNa in newly diagnosed chronic phase CML patients with an intermediate or low Sokal risk score. The primary end point was to compare the major molecular response (MMR) rate after 12 months between the treatment arms (intention-to-treat analysis).In a Nordic CML Study Group (NMCLSG: Denmark, Finland, Norway and Sweden) and Israel multicenter study we randomized 114 newly diagnosed CML patients in complete hematological remission following 3 months of IM 400 mg OD induction therapy. The study arms were IM (Glivec, Novartis) and the combination of IM and IFNa 2b (PegIntron, Schering-Plough). IM dose was fixed at 400 mg OD. IFNa was started at 30 μg/week but could be escalated to 50 μg/week or reduced down to 15 μg/week depending on tolerability. Molecular response was evaluated by blood RQ-PCR for BCR-ABL1 and was expressed on the international scale (IS).As of August 17, 2009, 79 patients were evaluable for primary endpoint and 47 of these were in MMR (59%) The rate of complete cytogenetic response (CCgR) was 68/79 (86%). Nineteen patients (17%) were considered as treatment failures (grade 4 nonhematological adverse event, refusal, loss of CCgR, progression to advanced phase, protocol violation or other reason).A final analysis will be performed when we have complete data on all randomized patients. The comparison by treatment arm on molecular and cytogenetic responses as well as other relevant data (treatment failures, patients off-treatment for protocol violations, refusal or toxicity) will be presented on site.Supported by European LeukemiaNet, WP 4.Simonsson: Novartis: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding. BjÖreman:BMS: Consultancy, Honoraria. Mustjoki:BMS: Honoraria. StrÖmberg:Novartis: Honoraria; BMS: Honoraria. Weiss Bjerrum:Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Gruber:Novartis: Research Funding. Nagler:Novartis: Consultancy. Porkka:Novartis: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding.

Published
2009
Full Text
View/download PDF

65. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

Author

Birgegård G, Björkholm M, Kutti J, Lärfars G, Löfvenberg E, Markevärn B, Merup M, Palmblad J, Mauritzson N, Westin J, and Samuelsson J

Subjects
Adult, Aged, Chronic Disease, Diarrhea chemically induced, Dose-Response Relationship, Drug, Female, Headache chemically induced, Heart Rate drug effects, Humans, Male, Middle Aged, Nausea chemically induced, Patient Compliance, Patient Dropouts, Prospective Studies, Thrombocytosis etiology, Myeloproliferative Disorders complications, Platelet Aggregation Inhibitors adverse effects, Platelet Aggregation Inhibitors therapeutic use, Quinazolines adverse effects, Quinazolines therapeutic use, Thrombocytosis drug therapy
Abstract

Background and Objectives: Although anagrelide is widely used in the treatment of thrombocythemia in myeloproliferative diseases, there is currently limited information on the efficacy and toxicity of its long-term use. This prospective study investigated clinical toxicity and efficacy of anagrelide during two years of treatment., Design and Methods: A multicenter, open, phase II study of anagrelide treatment was performed by the Swedish Myeloproliferative Disorder Study Group. The study included 60 patients with thrombocythemia due to myeloproliferative disease, 42 with essential thrombocythemia (ET), 17 with polycythemia vera (PV) and one with myelofibrosis (MF)., Results: Complete response (CR), defined as a platelet count <400x10(9)/L in symptomatic patients and < 600x10(9)/L in asymptomatic patients was achieved in 67% of the patients and partial response (PR) in 6%. The response rate was higher in patients with ET than in those with PV (p = 0.05). Primary treatment failure occurred in 27% due to lack of efficacy at a tolerable dose (n=13) or insufficient platelet response without side effects (n=3). In addition, another 14 patients withdrew from treatment before the end of the two-year period due to side effects. Side effects included palpitations (70%), headache (52%), nausea (35%), diarrhea or flatulence (33%), edema (22%) and fatigue (23%). Patients and doctors rated their satisfaction with the anagrelide treatment on a 10-grade scale from 7.6 at 3 months to >9 at 24 months. After two years, 50% (n=30) of the patients continued anagrelide treatment., Interpretation and Conclusions: Side effects and toxic discontinuation rates were higher than in previous studies, probably because this is the first long-term prospective study of the feasibility and toxicity of anagrelide treatment. Nevertheless, anagrelide is a valuable alternative for treatment of thrombocythemia in myeloproliferative disorders for patients who tolerate the drug well.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results